Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H12N2O3 |
Molecular Weight | 232.2353 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2
InChI
InChIKey=MHWLWQUZZRMNGJ-UHFFFAOYSA-N
InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
Molecular Formula | C12H12N2O3 |
Molecular Weight | 232.2353 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC432036/pdf/pnas00033-0067.pdf
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC432036/pdf/pnas00033-0067.pdf
Nalidixic acid is a quinolone antibacterial indicated for the treatment of urinary tract infections. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are generally resistant to the drug. It is suggested that nalidixic acid acts by inhibiting bacterial DNA gyrase.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/170053
Curator's Comment: Negligible amounts of nalidixic acid cross the blood brain barrier.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 |
110.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | NEGGRAM Approved UseNegGram (nalidixic acid, USP) is indicated for the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species. Disc susceptibility testing with the 30 mcg disc should be performed prior to administration of the drug, and during treatment if clinical response warrants. Launch Date-1.83772807E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7174858/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
NALIDIXIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
327.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7174858/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
NALIDIXIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7174858/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
NALIDIXIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
28 g single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 19 years Sex: F Population Size: 1 Sources: |
Disc. AE: Metabolic acidosis, Coma... AEs leading to discontinuation/dose reduction: Metabolic acidosis (1 patient) Sources: Coma (1 patient) |
150 mg/kg single, oral Overdose Dose: 150 mg/kg Route: oral Route: single Dose: 150 mg/kg Sources: |
unhealthy, 6 months n = 12 Health Status: unhealthy Condition: acute bacillary dysentery Age Group: 6 months Sex: unknown Population Size: 12 Sources: |
Disc. AE: Vomiting, Intracranial hypertension... AEs leading to discontinuation/dose reduction: Vomiting (12 patients) Sources: Intracranial hypertension (12 patients) Convulsions (2 patients) |
1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: acute bacillary dysentery Age Group: adult Sex: unknown Sources: |
Other AEs: Phototoxicity... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Coma | 1 patient Disc. AE |
28 g single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 19 years Sex: F Population Size: 1 Sources: |
Metabolic acidosis | 1 patient Disc. AE |
28 g single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 19 years Sex: F Population Size: 1 Sources: |
Intracranial hypertension | 12 patients Disc. AE |
150 mg/kg single, oral Overdose Dose: 150 mg/kg Route: oral Route: single Dose: 150 mg/kg Sources: |
unhealthy, 6 months n = 12 Health Status: unhealthy Condition: acute bacillary dysentery Age Group: 6 months Sex: unknown Population Size: 12 Sources: |
Vomiting | 12 patients Disc. AE |
150 mg/kg single, oral Overdose Dose: 150 mg/kg Route: oral Route: single Dose: 150 mg/kg Sources: |
unhealthy, 6 months n = 12 Health Status: unhealthy Condition: acute bacillary dysentery Age Group: 6 months Sex: unknown Population Size: 12 Sources: |
Convulsions | 2 patients Disc. AE |
150 mg/kg single, oral Overdose Dose: 150 mg/kg Route: oral Route: single Dose: 150 mg/kg Sources: |
unhealthy, 6 months n = 12 Health Status: unhealthy Condition: acute bacillary dysentery Age Group: 6 months Sex: unknown Population Size: 12 Sources: |
Phototoxicity | 1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: acute bacillary dysentery Age Group: adult Sex: unknown Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive | ||||
inconclusive | ||||
yes [IC50 0.3 uM] | ||||
yes [IC50 4.2 uM] | ||||
yes [IC50 78.3 uM] | ||||
Page: 1,6 |
yes [Inhibition 500 uM] | no (co-administration study) Comment: no effects on theophylline pharmacokinetics were reported Page: 1,6 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Multidrug resistance to antibacterial drugs of Salmonella enterica subsp. enterica strains isolated in Poland in the 1998-1999 period]. | 2001 |
|
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii]. | 2001 Dec |
|
Susceptibility of Arcobacter butzleri isolates to 23 antimicrobial agents. | 2001 Dec |
|
Synthesis, characterization and antitumor activity of quinolone-platinum(II) conjugates. | 2001 Dec 1 |
|
Quinolones and false-positive urine screening for opiates by immunoassay technology. | 2001 Dec 26 |
|
Campylobacter, Salmonella, Shigella and Escherichia coli in live and dressed poultry from metropolitan accra. | 2001 Dec 4 |
|
Enterococcal urinary tract infections: eight years experience at a regional hospital in Trinidad, West Indies. | 2001 Jan |
|
Enteric fever treatment failures: a global concern. | 2001 Jul-Aug |
|
Antibiotic resistance and sero-groups of shigella among paediatric out-patients in southwest Ethiopia. | 2001 Jun |
|
[Increasing incidence and the mechanism of resistance of nalidixic acid resistant Shigella sonnei]. | 2001 Nov |
|
Induction of pCW3-encoded tetracycline resistance in Clostridium perfringens involves a host-encoded factor. | 2001 Nov |
|
Susceptibility patterns of enteroaggregative Escherichia coli associated with traveller's diarrhoea: emergence of quinolone resistance. | 2001 Nov |
|
[Studies on halophilic vibrios causing a food poisoning outbreak in the city of Vladivostok]. | 2001 Nov-Dec |
|
Typhoid and paratyphoid fever: a 10-year retrospective study of 41 cases in a Parisian hospital. | 2001 Nov-Dec |
|
Tropical diarrhoea: new developments in traveller's diarrhoea. | 2001 Oct |
|
Epidemiological analysis of Salmonella enteritidis isolates in Singapore. | 2001 Oct |
|
Comparison of minimum inhibitory concentration values for fluoroquinolones against Escherichia coli causing urinary tract infection in both hospitalized patients and outpatients. | 2001 Oct |
|
Bacterial aetiology and anti-microbial resistance of childhood diarrhoea in Yemen. | 2001 Oct |
|
[Comparative study of the bacteriostatic and bactericidal activity of levofloxacin against Pasteurella strains isolated from man]. | 2001 Oct |
|
Antibiotic resistance in Escherichia coli isolates obtained from animals, foods and humans in Spain. | 2001 Oct |
|
Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992-98. | 2001 Oct |
|
[The current antimicrobial resistance situation in Swiss veterinary medicine]. | 2001 Oct |
|
Fluoroquinolone adverse effects and drug interactions. | 2001 Oct |
|
Association between cyclohexane resistance in Salmonella of different serovars and increased resistance to multiple antibiotics, disinfectants and dyes. | 2001 Oct |
|
Comparison of aztreonam against other antibiotics used in urinary tract infections. | 2001 Oct-Dec |
|
Epidemiology of shigellosis in Lagos, Nigeria: trends in antimicrobial resistance. | 2001 Sep |
|
Antimicrobial susceptibilities of Campylobacter strains isolated from broilers in the southern part of Japan from 1995 to 1999. | 2001 Sep |
|
Media for the isolation and enumeration of bifidobacteria in dairy products. | 2001 Sep 28 |
|
In vitro antibiotic susceptibility of bacteria isolated from EUS-affected fishes in India. | 2002 |
|
Incidence and molecular analysis of Vibrio cholerae associated with cholera outbreak subsequent to the super cyclone in Orissa, India. | 2002 Apr |
|
Salmonella enterica serotype Typhimurium DT104 isolated from humans, United States, 1985, 1990, and 1995. | 2002 Apr |
|
Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. | 2002 Apr |
|
Identification of an immunodominant drug efflux pump in Burkholderia cepacia. | 2002 Apr |
|
Serovars of Salmonella isolated from Danish turkeys between 1995 and 2000 and their antimicrobial resistance. | 2002 Apr 13 |
|
On the effect of covalently appended quinolones on termini of DNA duplexes. | 2002 Apr 24 |
|
Time-dependent toxicity in the long-term inhibition assay with Vibrio fischeri. | 2002 Feb |
|
Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. | 2002 Feb |
|
[Evolution of susceptibility of aerobic gram-negative aerobic bacilli to quinolones and fluoroquinolones in a university hospital (1992-2000)]. | 2002 Feb |
|
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. | 2002 Feb |
|
Green fluorescent protein-based biosensor for detecting SOS-inducing activity of genotoxic compounds. | 2002 Jan |
|
Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials. | 2002 Mar |
|
Emergence and rapid spread of tetracycline-resistant Vibrio cholerae strains, Madagascar. | 2002 Mar |
|
Inactivation of Escherichia coli O157:H7 on inoculated alfalfa seeds with ozonated water and heat treatment. | 2002 Mar |
|
Screening of antibiotic resistant inhibitors from local plant materials against two different strains of Staphylococcus aureus. | 2002 Mar |
|
Modified Pseudomonas agar: new differential medium for the detection/enumeration of Pseudomonas aeruginosa in mineral water. | 2002 Mar |
|
Comparison of aqueous commercial cleaners for effectiveness in removing Escherichia coli O157:H7 and Salmonella muenchen from the surface of apples. | 2002 Mar 25 |
|
Antimicrobial susceptibility patterns of Campylobacter jejuni strains isolated from hospitalized children in Athens, Greece. | 2002 May |
|
Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. | 2002 May |
|
Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. | 2002 May |
|
Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999. | 2002 May |
Sample Use Guides
1 g administered four times daily for one or two weeks (adults), 25 mg/lb/day (55 mg/kg/day), administered in four equally divided doses (pediatric use).
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10702570
The susceptibilities of the 15-nalidixic acid susceptible and 59 nalidixic acid-resistant isolates of P.mirabilis were tested against nalidixic acid. MIC50 values were 8 mg/L and >512 mg/L, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:23:22 UTC 2023
by
admin
on
Sat Dec 16 16:23:22 UTC 2023
|
Record UNII |
3B91HWA56M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
663
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
||
|
WHO-ATC |
J01MB02
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
||
|
WHO-VATC |
QJ01MB02
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
||
|
NCI_THESAURUS |
C255
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7240
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
100000092361
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
1450
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
m7714
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | Merck Index | ||
|
3B91HWA56M
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
4421
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
206-864-7
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
100147
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
618425
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
ALTERNATIVE | |||
|
CHEMBL5
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
62070
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
D009268
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
82174
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
C47630
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
3241
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
DTXSID3020912
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
1875
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
Nalidixic Acid
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
NALIDIXIC ACID
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
389-08-2
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
SUB09138MIG
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
DB00779
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY | |||
|
3B91HWA56M
Created by
admin on Sat Dec 16 16:23:23 UTC 2023 , Edited by admin on Sat Dec 16 16:23:23 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |